Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 12th Preview)
-
Precision oncology diagnostics
Roche’s Foundation Medicine rebranded Saga Diagnostics’ minimal residual disease test after the $595 million acquisition earlier this year, positioning the assay for new indications beyond breast cancer. The test now called FoundationOne MRD uses tumor-informed selection of structural variants from whole-genome sequencing, followed by digital PCR on circulating tumor DNA, with an approximately 48-hour turnaround. The company emphasized the choice of structural variants to improve sensitivity and specificity, including reduced false calls linked to sequencing errors seen in point-mutation-only approaches. Foundation Medicine also argued structural variants are more stable over time than point mutations as disease evolves. Roche described the test as flexible for use at any laboratory by pairing its workflow with compatible digital PCR systems, including its Digital Lightcycler. The rebrand signals an effort to expand MRD testing footprints while leveraging the molecular approach that helped drive the Saga deal.
-
AI-augmented pathology biomarker workflows
Leica Biosystems expanded a computational pathology collaboration with AstraZeneca and Daiichi Sankyo, building an end-to-end research workflow to quantify the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small cell lung cancer. The joint work uses AstraZeneca’s Quantitative Continuous Scoring (QCS) algorithm paired with Leica’s immunohistochemistry assay development, scanners, and image management tools. The collaboration delivers a reproducible workflow using Leica platforms including BOND RX and BOND-III stainers, Aperio GT 450 scanners, and the Aperio HALO AP image management system. Leica said the TROP2 NMR algorithm will be distributed via the Aperio AI Store as a research tool only. Separately, DiaDeep and Leica announced a commercial reseller partnership to bring DiaDeep’s oncology pathology AI applications into the Aperio AI Store, integrating within existing digital pathology workflows for pathologists. The deal underscores a push to make AI diagnostics more plug-and-play in routine labs.
-
Digital lab and sequencing platform scaling for ctDNA
Hartwig Medical Foundation expanded its partnership with Ultima Genomics by adopting the Ultima UG200 sequencing platform to scale whole-genome-informed ctDNA monitoring. The partners said the goal is to increase throughput while reducing the overall cost of cancer research and testing. Their focus includes further validation and implementation of Ultima’s paired plus minus sequencing (ppmSeq) technology to support longitudinal MRD and minimal residual disease monitoring workflows. They also plan to build end-to-end workflows so clinical genomics teams can implement Ultima data analysis in-house. The update comes as the broader field continues to shift toward more quantitative liquid biopsy strategies that can support repeated sampling across treatment timelines, not just single time-point assays.
-
Cell and gene therapy platform advances
T-Curx received Swissmedic clinical trial approval for its nonviral, Siglec-6-targeted CAR T program TCX-001, clearing a first-in-human phase I study in Switzerland. The company said it plans to submit to the EMA to expand the trial into Germany. The trial will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation. The approval marks a regulatory step for a platform positioned around a nonviral lead CAR T approach.
-
Rare disease funding and IPO momentum
Ethyreal launched with $101 million across venture rounds to develop a long-acting anti-TSHR monoclonal antibody, ETHY-001, for Graves’ disease and thyroid eye disease. The company disclosed preclinical data at the Endocrine Society meeting and said the funding is intended to push the program toward clinical readouts this year. The financing syndicate initially included Atlas Venture and Medicxi Ventures, followed by additional investors in a series A and series B. The launch highlights continuing investment appetite for long-acting biologics that can simplify chronic dosing regimens. Separately, Parabilis Medicines priced an upsized IPO that raised $745 million, supporting its peptide platform lead program zolucatetide for a rare tumor type. The IPO adds to evidence that investors are still funding entry-stage companies with focused, target-access strategies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.